Showing results (581-590 of 3,353) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
The Lancet. Oncology|June 28, 2016
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trialAmelia O Clive, Hazel Taylor, Lee Dobson, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
The Lancet. Oncology|September 9, 2017
Radiotherapy for the treatment of malignant pleural mesotheliomaMarc de Perrot, Licun Wu, Matthew Wu, et al.
The Lancet. Oncology|June 18, 2016
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trialKoichi Goto, Yuichiro Ohe, Taro Shibata, et al.
The Lancet. Oncology|June 22, 2016
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trialSophie Piperno-Neumann, Marie-Cécile Le Deley, Françoise Rédini, et al.
The Lancet. Oncology|July 15, 2017
Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trialFranco Locatelli, Maria Ester Bernardo, Alice Bertaina, et al.
The Lancet. Oncology|January 6, 2018
Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approachJane Ireson, Georgina Jones, Matthew C Winter, et al.
The Lancet. Oncology|November 5, 2020
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trialIan Smith, John Robertson, Lucy Kilburn, et al.
Pageof 336